The development of a pharmacovigilance system in Bahrain

Abdulrasool, Zainab

doi:10.1016/j.jsps.2022.03.009

Cited by 1 publication

(2 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The main barriers for adverse drug reaction reporting have been shown in (Table 3). (6) There is no determined reporting form, in other words, the absence of a special center for official Pharmacovigilance within the country. Qassim et al (7) Lack of proper knowledge and weakness in the practice to complete the process of documenting side effects.…”

Section: Resultsmentioning

confidence: 99%

“…Examining the results from these studies, it is no secret to anyone that the main obstacle in the way of adverse drug reaction reporting is the lack of knowledge and awareness about pharmacovigilance in general (1,(4)(5)(6)(7)(8)(9)(10)(11) . This lack of awareness includes how to fill the forms for pharmacovigilance, how to distinguish which adverse events should be recorded, the steps to document the ADR and to which side they will be sent.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Detection of Main Barriers for Adverse Drug Reactions Reporting in The Middle East Countries: Review article

Hussein¹,

Hassan²

2023

The Egyptian Journal of Hospital Medicine

View full text Add to dashboard Cite

Background: For years, specialists have been interested on the verge of documentation of adverse drug reactions because of its great importance. The countries of the Middle East have also kept pace with this mission and developed in the past years. Like any other project, this documentation process is accompanied by several problems that will negatively affect the objectives set in this area. Objective: The aim of the current study is to know the main barriers regarding the process of adverse drug reactions in the Middle East area. Patients and methods: In October 2022, a manual search of the literary databases PubMed and Google Scholar has done. The 102 articles were manually screened. Studies that have been published between 2012 and 2022 were eligible. Results: From the 102 publications that underwent manual screening, 26 research articles from 12 different countries qualified for inclusion in the study. Lack of enthusiasm, a professional atmosphere for the conduct of pharmacovigilance, a general lack of knowledge and awareness concerning pharmacovigilance and not enough time for reporting are the main barriers for adverse drug reactions. Conclusion:According to the results, the lack of knowledge or awareness of pharmacovigilance practices and the absence of mechanisms that assist recording in terms of enough time, motivation, or the environment as a whole are the two most significant causes of underreporting.

show abstract

Section: Resultsmentioning

confidence: 99%